Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30924722 | 1.00 | PRCP (0.58) | PRCPGAASLC22A1RECQLTSHR | |
| Hydrochloric Acid SCHEMBL28282197 | 0.98 | GAA (0.59) | PRCPGAASLC22A1RECQLTSHR | |
| SCHEMBL9587010 | 0.79 | PRCP (0.58) | PRCPGAASLC22A1RECQLTSHR | |
| SCHEMBL30218848 | 0.79 | PRCP (0.53) | PRCPGAASLC22A1RECQLTSHR | |
| SCHEMBL1011425 | 0.79 | PRCP (0.53) | PRCPGAASLC22A1RECQLTSHR | |
| SCHEMBL24017043 | 0.78 | PRCP (0.70) | PRCPGAASLC22A1RECQLTSHR | |
| SCHEMBL1566232 | 0.78 | PNMT (0.42) | PRCPMAPT | |
| SCHEMBL16799768 | 0.78 | PRCP (0.70) | PRCPGAASLC22A1RECQLTSHR | |
| SCHEMBL30368634 | 0.78 | PRCP (0.70) | PRCPGAASLC22A1RECQLTSHR | |
| Hydrochloric Acid SCHEMBL1124323 | 0.77 | GAA (0.54) | PRCPGAASLC22A1RECQLTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174616-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| CN-110511209-A | It can be used as the indole carboxamides compound of kinase inhibitor | BRISTOL MYERS SQUIBB CO | 2019-11-29 | — | — | CN | disclosed |
| CN-110139861-A | Pyran derivatives as inhibitors of CYP11A1 (cytochrome P450 monooxygenase 11A1) | 奥赖恩公司 | 2019-08-16 | — | — | CN | disclosed |
| CN-109863145-A | Novel tetrahydroisoquinoline and tetrahydronaphthyridine compounds for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2019-06-07 | — | — | CN | disclosed |
| CN-109562169-A | anti-CD 98 antibodies and antibody drug conjugates | 艾伯维公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109563167-A | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | 艾伯维公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-106103426-B | 8- (piperazine -1- base) -1,2,3,4- tetrahydro-isoquinoline derivative | 爱杜西亚药品有限公司 | 2019-03-19 | — | — | CN | disclosed |
| CN-104884453-B | Anthelmintic compounds and compositions and methods of using the same | 梅里亚股份有限公司 | 2018-06-22 | — | — | CN | disclosed |
| CN-105294654-B | ALK kinase inhibitors and its preparation method and application | 北京浦润奥生物科技有限责任公司 | 2018-01-09 | — | — | CN | disclosed |
| CN-105228996-B | Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors | 百时美施贵宝公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-104011021-B | heterocyclic derivatives and their use as prostaglandin D2 receptor modulators | 埃科特莱茵药品有限公司 | 2016-08-24 | — | — | CN | disclosed |
| US-9255090-B2 | Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-09 | — | — | US | disclosed |
| US-20150252036-A1 | Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| CN-103958478-A | Novel bicyclic dihydroisoquinolin-1-one derivatives | HOFFMANN LA ROCHE | 2014-07-30 | — | — | CN | disclosed |
| US-8575158-B2 | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-05 | — | — | US | disclosed |
| EP-2590944-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109685-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-05-02 | — | — | US | disclosed |
| CN-102869250-A | 4- (N-azacycloalkyl) anilide derivatives as potassium channel modulators | VALEANT PHARMACEUTICALS INT | 2013-01-09 | — | — | CN | disclosed |
| WO-2012004722-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-01-12 | — | — | WO | disclosed |
| CN-1261350-A | Tetrahydroisoquinoline derivatives as modulators of the dopamine D3 receptor | SMITHKLINE BEECHAM PLC (GB) | 2000-07-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252036-A1 | Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators | PTGDR, PTGER1, PTGDR2 | PRCP 3669/4885GAA 4674/4885SLC22A1 3540/4885 |
| US-20240174616-A1 | HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | PRCP 1601/4885GAA 73/4885SLC22A1 3596/4885 |
| US-20130109685-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | PTGER1, PTGDR, PTGDR2 | PRCP 2631/4885GAA 4326/4885SLC22A1 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.